id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-343973-n5ogyxz7	Ip, Andrew	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients—An observational study	2020-08-13		.txt	text/plain	4322	239	43	In this retrospective observational cohort study drawn from electronic health records we sought to describe the association between mortality and hydroxychloroquine or tocilizumab therapy among hospitalized COVID-19 patients. Subsequently, an observational cohort study of 1376 hospitalized patients from a New York hospital using propensity modeling found no significant association between hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32) [14] . A recently reported randomized Brazilian trial enrolling 504 hospitalized SARS-CoV-2 confirmed patients with mild-to-moderate disease (defined as not requiring significant supplemental oxygen support) found that a 7-day course of hydroxychloroquine either with azithromycin or alone did not result in better clinical outcomes as measured by a seven-level ordinal scale at 15 days [16] . In this observational cohort study we report our survival outcomes with hydroxychloroquine and tocilizumab among hospitalized patients with COVID-19.	./cache/cord-343973-n5ogyxz7.txt	./txt/cord-343973-n5ogyxz7.txt